Rhabdomyosarcoma, Embryonal clinical trials
The registry lists 9 studies for Rhabdomyosarcoma, Embryonal across 7 countries. 3 are recruiting or about to start. 5 of them are mainly about Rhabdomyosarcoma, Embryonal (how this is decided). Per ClinicalTrials.gov, last updated 2026-10-26.
Get an email when these change. Save the Rhabdomyosarcoma, Embryonal studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
National Cancer Institute (NCI) (3) · Children's Oncology Group (3) · N.N. Petrov National Medical Research Center of Oncology (1) · Novartis Pharmaceuticals (1) · Children's Hospitals and Clinics of Minnesota (1)
What is being tested here
Drugs under test in Rhabdomyosarcoma, Embryonal studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Cyclophosphamide | 1 | 3 | 3 |
| Dinutuximab | 1 | 1 | 1 |
| Dactinomycin | 0 | 2 | 2 |
| Vincristine | 0 | 2 | 2 |
| Vinorelbine | 0 | 1 | 1 |
| Interleukin 7 | 0 | 0 | 1 |
| Imatinib | 0 | 0 | 1 |
| Dasatinib | 0 | 0 | 1 |
| Ganitumab | 0 | 0 | 1 |
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Who these studies take
Of the 3 Rhabdomyosarcoma, Embryonal studies recruiting now, 0 (0%) set no upper age limit and 2 (67%) stop at 75 or younger. 3 (100%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (33%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 3 (100%) | 3 (100%) |
| 18 | 3 (100%) | 3 (100%) |
| 30 | 1 (33%) | 1 (33%) |
| 40 | 1 (33%) | 1 (33%) |
| 50 | 1 (33%) | 1 (33%) |
| 65 | 1 (33%) | 1 (33%) |
| 75 | 1 (33%) | 1 (33%) |
| 85 | 1 (33%) | 1 (33%) |
Across all 9 studies, recruiting or not: 78% stop at 75 or younger and 67% at 65; 100% take children; 0% are for women only and 0% for men only; 11% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 9 of 9. search them.
- International PPB/DICER1 RegistryRecruitingNCT033821581 country
- Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative RhabdomyosarcomaRecruitingNCT05304585Phase 34 countries
- Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue SarcomasRecruitingNCT06669013Phase 31 country
- Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk RhabdomyosarcomaActive, not recruitingNCT02567435Phase 35 countries
- A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients With High Risk RhabdomyosarcomaActive, not recruitingNCT04994132Phase 35 countries
- Genetic Mutational Analysis of Saliva or Buccal Mucosa Samples From Patients With Embryonal or Alveolar RhabdomyosarcomaActive, not recruitingNCT032963711 country
- Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar RhabdomyosarcomaTerminatedNCT03041701Phase 1/21 country
- Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or NeuroblastomaCompletedNCT00923351Phase 1/21 country
- Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare DiseasesCompletedNCT00154388Phase 2